Loading stock…

Gilead Sciences, Inc. (GILD) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Gilead Sciences, Inc.

GILDMarket cap $182BPrice $146.8

Country🇺🇸United States

SectorHealthcare

IndustryBiotechnology

Develops antiviral drugs that treat HIV, hepatitis, and other life-threatening diseases affecting millions worldwide. Their HIV treatments generate over $15 billion annually, making them one of biotech's biggest cash machines.

In Bastion Portfolios?

52W Return+21%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+3%4

Revenue Forecast

Rev CAGR (1y)+4%4

Rev CAGR (3y)+5%4

Rev CAGR (5y)+5%5

Earnings Forecast

EPS Growth Y+1Loss1

EPS Growth Y+20%5

EPS Growth Y+3+6%6

Quality

Margins

EBIT Margin39%9

Net Income Margin-11%1

Free Cash Flow Margin42%10

Debt

Net Debt/EBITDA1.45

Efficiency

ROE-21%1

ROA-6%1

Earnings Stability33

GEAR+AVERAGE45

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)175

P/E Ratio (Forward 3y)145

P/BV15.41

EV Multiples

EV/EBITDA Fwd341

EV/EBIT Fwd621

Yield

Free Cash Flow Yield7.1%8

Dividend Yield2.2%6

Momentum

Short term

1 month return+1%8

3 month return+9%8

YTD return+22%8

Mid term

Price vs 52wHigh95%10

1 year return+27%8

Long term

3 year return+116%8

5 year return+158%8

Risk Shield

Price Risk

Beta0.39

Volatility26%8

Free Cash Flow

Free Cash Flow Margin42%10

Free Cash Flow Yield7.1%8

Quality

ROCE29%10

Earnings Stability33

Net Debt/EBITDA1.45

02Growth

Is it actually growing, and how fast?

GILDGilead Sciences

Revenue FY25$29.4B

GROWTH RATING↗

WEAK34 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+3%4

Revenue, next 1Y+4%4

Revenue, next 3Y, CAGR+5%4

Revenue, next 5Y, CAGR+5%5

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27E0%5

EPS growth, FY28E+6%6

GROWTH ASSESSMENT

STRENGTHS

None flagged.

WATCH

A mid-pack grower, ahead of 34% of companies worldwide.

Revenue is set to grow 5%/yr over the next 3 years, a little behind the market.4/10

Revenue grew 3%/yr over the last 3 years and is set to keep growing around 5%/yr.

Over five years revenue is set to grow 5%/yr, about average versus companies worldwide.5/10

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Modest Grower

A middle-of-the-pack grower. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY STRONG91 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+1%8

3-month return+9%8

YTD return+22%8

MID & LONG-TERM▾SCORE

% of 52-week high95%10

1-year return+27%8

3-year return+116%8

5-year return+158%8

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +116% over three years and +158% over five, ahead of 70% of the market.

It's up 27% over the past year, now sitting right at its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+1%), over three months (+9%) and so far this year (+22%).

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally, and the stock trades near its highs. The market is fully behind it — a core fit for momentum strategies.

04Value

Are you paying a fair price for it?

Stop guessing on Gilead. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

GILDGilead Sciences

Revenue FY25$29.4B

GROWTH RATING↗

WEAK34 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+3%4

Revenue, next 1Y+4%4

Revenue, next 3Y, CAGR+5%4

Revenue, next 5Y, CAGR+5%5

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27E0%5

EPS growth, FY28E+6%6

GROWTH ASSESSMENT

STRENGTHS

None flagged.

WATCH

A mid-pack grower, ahead of 34% of companies worldwide.

Revenue is set to grow 5%/yr over the next 3 years, a little behind the market.4/10

Revenue grew 3%/yr over the last 3 years and is set to keep growing around 5%/yr.

Over five years revenue is set to grow 5%/yr, about average versus companies worldwide.5/10

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Modest Grower

A middle-of-the-pack grower. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY STRONG91 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+1%8

3-month return+9%8

YTD return+22%8

MID & LONG-TERM▾SCORE

% of 52-week high95%10

1-year return+27%8

3-year return+116%8

5-year return+158%8

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +116% over three years and +158% over five, ahead of 70% of the market.

It's up 27% over the past year, now sitting right at its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+1%), over three months (+9%) and so far this year (+22%).

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally, and the stock trades near its highs. The market is fully behind it — a core fit for momentum strategies.

04Value

Are you paying a fair price for it?

Stop guessing on Gilead. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community